Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03.
|
Amendments to Articles of Incorporation or Bylaws; Change
in Fiscal Year. |
it has effected a one-for-ten reverse split (the Reverse Stock
Split) of the Companys outstanding shares of common stock,
together with a corresponding proportional reduction in the
number of authorized shares of the Companys capital stock (the
Authorized Share Reduction). To effectuate the Reverse Stock
Split and the Authorized Share Reduction, the Company filed a
Certificate of Amendment of the Companys Amended and Restated
Certificate of Incorporation (the Amendment) with the Secretary
of State of the State of Delaware. to and upon the effectiveness
of the Amendment at 7:00 a.m., Eastern Standard Time, on May 5,
2017, each ten shares of the Companys common stock, par value
$0.0001 per share, issued and outstanding at the effective time
were reclassified and combined into one share of common stock,
par value $0.0001 per share, of the Company and the number of
shares of common stock and preferred stock the Company is
authorized to issue was reduced to 50 million and 10 million,
respectively.
(Olde Monmouth) to act as exchange agent for the Reverse Stock
Split. Olde Monmouth will manage the exchange of old, pre-Reverse
Stock Split shares for new post-Reverse Stock Split shares.
Stockholders will receive a letter of transmittal providing
instructions for the exchange of their shares. Record
stockholders who hold their shares in street name will be
contacted by their banks or brokers with any instructions. For
further information, stockholders and securities brokers should
contact Olde Monmouth at (732) 872-2727 or
[email protected].
incorporated herein by reference.
| Item 7.01. |
Regulation FD Disclosure.
|
effectiveness of the Reverse Stock Split discussed under Item
5.03 of this report.
Exhibit 99.1 and is incorporated by reference herein.
| Item 9.01 |
Financial Statements and Exhibits.
|
|
Exhibit No.
|
Description
|
|
|
3.1
|
Certificate of Amendment of Amended and Restated
Certificate of Incorporation of Rexahn Pharmaceuticals, Inc. |
|
|
99.1
|
Rexahn Pharmaceuticals, Inc. press release dated May 5,
2017, announcing the effectiveness of the Reverse Stock Split and Authorized Share Reduction |
About Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)
Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Recent Trading Information
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed its last trading session down -0.07 at 3.85 with 269,258 shares trading hands.
